The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The promise and impending approval of CELMoDs for multiple myeloma
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the promise and impending approval of cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory (R/R) multiple myeloma (MM), highlighting key trials that will support regulatory decisions. Dr Schjesvold notes that the results of the SUCCESSOR-2 trial (NCT05552976) are particularly exciting, showing a doubling of progression-free survival (PFS) with mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus Kd in a heavily pretreated population. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
